IO Biotech, Inc. Common Stock
IOBTIO Biotech, Inc. (IOBT) is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for the treatment of cancer and autoimmune diseases. The company leverages its proprietary immune modulation platform, referred to as Immuno-Oncology Biotech (IOBT), to design therapies that stimulate the body's immune system to target disease more effectively. Founded to advance personalized and combination immune treatments, IO Biotech aims to improve patient outcomes through its novel therapeutic candidates.
Company News
IO Biotech presented pre-clinical data on two therapeutic cancer vaccine candidates, IO112 and IO170, at the Society for Immunotherapy of Cancer's Annual Meeting. The candidates target arginase 1 and TGF-β, demonstrating potential anti-tumor activities and immune microenvironment modulation.
Oncology drug delivery is advancing through nanomedicine technologies, with companies developing innovative platforms to improve drug bioavailability, reduce toxicity, and enhance therapeutic effectiveness in cancer treatments.
IO Biotech (IOBT) falls 25% despite achieving the clinical milestone of enrolling 225 patients in the advanced melanoma study evaluating the IO102-IO103/Keytruda combo.
